PD-L1 (Woodchuck) / TCR Activator Mammalian Expression Kit

Catalog #
79455
$590 *
Size: 500 Reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The recombinant expression vectors are designed to express human engineered T cell receptor (TCR) activator and woodchuck (groundhog, Marmota monax) PD-L1 (GenBank Accession #HQ403651) in mammalian cells. The transfected cells can be used in conjunction with Woodchuck PD-1/NFAT Reporter/Jurkat T cells (BPS #79456) to study the interactions of PD-1 with PD-L1 ligand in a cellular context and screen for modulators of this signaling pathway.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
Groundhog, Marmota Monax, PD-L1, Programmed Cell Death 1 Ligand 1, CD274, B7 Homolog 1, B7-H1, TCR
Product Info
Storage and Usage
Citations
Materials Required But Not Supplied
  • • HEK293 cell and its growth medium or other cell lines
  • • Transfection reagent for mammalian cell line [We use Lipofectamine™ 2000 (life technologies, #11668027). However, other transfection reagents work equally well.]
  • Woodchuck PD-1/ NFAT reporter-Jurkat cell line (BPS Bioscience #79456)
  • • Opti-MEM I Reduced Serum Medium (life technologies #31985-062) 
  • • Assay Medium: RPMI1640 + 10% FBS + 1% Penicillin/Streptomycin
  • • 96-well tissue culture treated white clear-bottom assay plate (Corning, #3610)
  • ONE-Step™ Luciferase Assay System (BPS Bioscience, #60690)
  • • Luminometer
  • • Anti-woodchuck PD-1 or PD-L1 neutralizing antibodies (Fisher Scientific #50-146-65, clone #MIH5)
Format

COMPONENTS:

Background
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated Tcells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.